Metformin monotherapy for type 2 diabetes mellitus
Article 2005 en
Authors
AS
Antonio Sáenz
IF
Inmaculada Fernandez-Esteban
AM
A.L. Mataix
Abstract
1 min read
Metformin may be the first therapeutic option in the diabetes mellitus type 2 with overweight or obesity, as it may prevent some vascular complications, and mortality. Metformin produces beneficial changes in glycaemia control, and moderated in weight, lipids, insulinaemia and diastolic blood pressure. Sulphonylureas, alpha-glucosidase inhibitors, thiazolidinediones, meglitinides, insulin, and diet fail to show more benefit for glycaemia control, body weight, or lipids, than metformin.
Khalid M. Alkharfy, Nasser M. Al‐Daghri, Shaun Sabico, Abdulaziz M. Al-Othman, Osama Moharram, Majed S. Alokail, Yousef Al‐Saleh, Sudhesh Kumar, George Chrousos
Petar Seferović, Mark C. Petrie, Gerasimos Filippatos, Stefan D. Anker, Giuseppe Rosano, Johann Bauersachs, Walter J. Paulus, Michel Komajda, Francesco Cosentino, Rudolf A. de Boer, Dimitrios Farmakis, Wolfram Doehner, Ekaterini Lambrinou, Yu. M. Lopatin, Massimo Piepoli, Michael J. Theodorakis, Henrik Wiggers, John Lekakis, Alexandre Mebazaa, Mamas A. Mamas, Carsten Tschöpe, Arno W. Hoes, Jelena P. Seferović, Jennifer Logue, Theresa A. McDonagh, Jillian Riley, Ivan Milinković, Marija Polovina, Dirk J. van Veldhuisen, Mitja Lainščak, Aldo Maggioni, Frank Ruschitzka,
Polyxeni Nikolakopoulou, Antonios Chatzigeorgiou, Ioannis Kourtzelis, Louiza Toutouna, Jimmy Masjkur, Carina Arps‐Forker, Steven Poser, Jan Rozman, Birgit Rathkolb, Juan Antonio Aguilar‐Pimentel, Lore Becker, Thomas Klopstock, Irina Treise, Dirk H. Busch, Johannes Beckers, Kristin Moreth, Raffi Bekeredjian, Lillian Garrett, Sabine M. Hölter, Annemarie Zimprich, Wolfgang Wurst, Robert Brommage, Oana V. Amarie,
.webp){kind=small}
Discussion(0)
No comments yet. Be the first to comment.